These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15673788)

  • 1. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.
    Ginsburg AS; Lee J; Woolwine SC; Grosset JH; Hamzeh FM; Bishai WR
    Antimicrob Agents Chemother; 2005 Feb; 49(2):853-6. PubMed ID: 15673788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin treatment of tuberculosis.
    Gosling R; Gillespie S
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3642; author reply 3642-3. PubMed ID: 15328148
    [No Abstract]   [Full Text] [Related]  

  • 4. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
    Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of subconjunctival injection of moxifloxacin in humans.
    Matsuura K
    Graefes Arch Clin Exp Ophthalmol; 2013 Mar; 251(3):1019-20. PubMed ID: 22552573
    [No Abstract]   [Full Text] [Related]  

  • 6. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
    Grossi O; Caillon J; Arvieux C; Jacqueline C; Bugnon D; Potel G; Hamel A
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3401-3. PubMed ID: 17576849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of moxifloxacin in the prophylaxis of post-surgical endophthalmitis].
    Villalobos PA; Valle DD
    Arch Soc Esp Oftalmol; 2010 Oct; 85(10):323-4. PubMed ID: 21168055
    [No Abstract]   [Full Text] [Related]  

  • 9. Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis.
    Djukic M; Böttcher T; Wellmer A; Gerber J; Brocke VV; Eiffert H; Nau R
    Neurocrit Care; 2005; 2(3):325-9. PubMed ID: 16159084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
    Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Moxifloxacin, a novel extended spectrum fluoroquinolone in the treatment of severe infectious inflammatory diseases].
    Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2005; 50(2-3):64-72. PubMed ID: 16308942
    [No Abstract]   [Full Text] [Related]  

  • 13. [New indications for novel fluoroquinolones: moxifloxacin in the treatment of nosocomial infections].
    Beloborodova NV; Popov DA; Vostrikova TIu; Bachinskaia EN; Kuznetsova ST
    Antibiot Khimioter; 2009; 54(1-2):25-6, 28-30. PubMed ID: 19499714
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin punctum plug for sustained drug delivery.
    Chee SP
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):340-9. PubMed ID: 22191856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
    Alffenaar JW; de Vries PM; Luijckx GJ; van Soolingen D; van der Werf TS; van Altena R
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2293-5. PubMed ID: 18362186
    [No Abstract]   [Full Text] [Related]  

  • 18. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
    Mohapatra PR
    Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.
    Stass H; Rink AD; Delesen H; Kubitza D; Vestweber KH
    J Antimicrob Chemother; 2006 Sep; 58(3):693-6. PubMed ID: 16895940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
    Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.